Triple negative breast cancer (TNBC) is characterized by the lack of human epidermal growth factor receptor-2 (HER2), estrogen receptor and progesterone receptor expression (Wolff et al., 2013), accounting for 10%–20% of all BC patients (Alam et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.